Company*
(Country; Symbol)

University/
Nonprofit@

Type Of Agreement

Product Area

Details (Date)


Accelrys
Inc.
(ACCL)

Boston University

Distribution agreement

Two new software methods for studying protein-protein docking

Accelrys will distribute the ZDOCK and RDOCK algorithms under undisclosed terms (6/15)

Aclara
BioSciences
Inc.
(ACLA)

Tokyo
Metropolitan
Institute of
Medical Science

Collaboration

They will evaluate
samples from breast
cancer patients

Aclara's eTag technology will be used to validate candidate biomarkers; Aclara will fund the
work and has rights to develop
resulting diagnostics (6/14)

AEterna Zentaris
Inc.
(Canada; AEZS)

German
Research
Center for
Biotechnology

License
agreement

Deal covering disorazoles, a class of natural products with potential
cancer applications

Zentaris GmbH gets an exclusive global license in exchange for an up-front payment, annual
license fees, and milestone and royalty payments (7/6)

Agilent
Technologies
Inc.
(NYSE:A)

Translational
Genomics
Research Institute

Collaboration

Oligonucleotide microarray technology called comparative genomic
hybridization

TGen gets early access to the technology, which will be applied to identifying and locating genetic alterations that contribute to cancer (6/8)

AnalytiCon
Discovery
GmbH*
(Germany)

Memorial Sloan-Kettering Cancer Center

Collaboration

Deal to combine technologies to discover and develop drugs for cancer

They will use AnalytiCon's natural products and chemistries with the center's biology and screening technologies; terms were not disclosed (7/23)

Athersys Inc.*

National Heart, Lung and Blood Institute

Cooperative Research and Development Agreement

To jointly develop and apply stem cell technology for treating cardiovascular disease

They will use Athersys' MAPC technology that is based on an adult-derived stem cell, as well as its genomics technologies, in the effort (5/20)

Australian
Cancer Technology
Ltd.
(Australia;
ASX:ACU)

Memorial Sloan-Kettering Cancer Center

Agreement

The center will use the GPI-0100 adjuvant in a series of clinical trials in cancer indications

The deal was made with Galenica Pharamceutcials Inc.; ACT's acquisition of Galenica was finalized the next day (6/22); second deal involves the center studying PI-0100 vaccinations in lymphomas and leukemias (7/1)

Bionomics Ltd.
(Australia; OTC
BB:BMICY)

Louisiana State
University Health
Sciences Center

Collaboration

The school's gene-delivery technology will be used to deliver gene expression-silencing molecules to solid tumors

Bionomics will have commercialization rights on resulting cancer treatments (7/30)

Bionomics
Ltd.
(Australia;
OTC BB:BMICY)

University of Wisconsin Medical School

Collaboration

The deal centers on an animal model of epilepsy

Bionomics will provide UWMS the model and get access to resulting intellectual property (7/7)

Biosystemix
Ltd.*
(UK)

S2K

Partnership

To develop computational models for disease susceptibility, progression and response

Biosystemix will work with S2K, a consortium of genomics researchers funded by Genome Canada and Genome Quebec (6/14)

BioTrove Inc.*

Stanford University

License
agreement

For patent applications
covering the use of
microarray technology

BioTrove licensed use of a through-hole-structured micro-array to perform PCR; terms were not disclosed (7/15)

Cellectis SA*
(France)

Four research
centers in Germany

License
agreements

The centers got rights to technology for replacing or inserting genes by homologous recombination

The centers gained nonexclusive sublicenses to the technology under undisclosed terms; the deal was brokered by Ascenion GmbH (5/26)

Clinomics
Biosciences Inc.
(subsidiary of
Cytomyx Holdings
plc; UK; AIM:CYX)

H. Lee Moffitt Cancer Center and Research Institute

Collaboration

To develop new technologies for use in cancer research

The initial work will focus on use of Clinomics' Tissue Micro Array technologies to improve the diagnosis and classification of primary tumors (7/13)

CytRx
Corp.
(CYTR)

University of Massachusetts Medical School

Expanded collaboration

CytRx has an option to license UMMS discoveries over three years in RNAi, diabetes, obesity, neuro-degenerative diseases and cytomegalovirus

CytRx will make certain cash payments over two years in consideration of invention disclosures, then could make payments to negotiate exclusive licenses to the discoveries (7/19)

CytRx
Corp.
(CYTR)

Imperial College London

License agreement

The college's drug-screening method using a nuclear hormone co-repressor that regulates fat accumulation

CytRx got an exclusive license to the technology in exchange for a license fee and potential milestone payments and royalties on resulting sales (5/20)

DOR BioPharma
Inc.
(AMEX:DOR)
and Thomas Jefferson
University

U.S. Army's Medical Research Institute of Infectious Diseases

Cooperative Research and Development Agreement

To advance development of DOR's mucosally delivered vaccine for botulinum toxin

USAMRIID will supply antigens and reagents, while DOR and the university will develop and test formulations (6/16)

Entelos Inc.*

American Diabetes Association

Collaboration

To develop an in silico research platform based on a non-obese diabetic mouse

The platform initially will be used by Entelos and certain research laboratories to address scientific questions related to Type I diabetes (6/9)

Genentech
Inc.
(NYSE:DNA)

Cancer Research Technology (UK)

License agreement

Genentech gets exclusive worldwide rights to patents covering an oncology target

Genentech plans to evaluate protein therapeutics against the target; terms were not disclosed (7/20)

Generex
Biotechnology
Corp.
(Canada; GNBT)

Saint Savas Cancer Center (Greece)

Collaboration

To use modified peptide antigens to stimulate cancer patients' immune cells

The work, involving Generex subsidiary Antigen Express, is designed to lead to trials of a vaccine in patients with ovarian cancer (6/1)

GenPhar Inc.*

U.S. Army

Amended contract

To develop and test multivalent vaccines for Marburg and Ebola viruses

The funding increased from $1M to $6M over the next two years; GenPhar intends to contract with the Medical University of South Carolina to perform some services (7/30)

Genzyme
Corp.
(GENZ)

Project HOPE

Partnership extension

To provide enzyme-replacement therapy to Gaucher's patients around the world

Under the Gaucher Initiative program, Genzyme donates Ceredase and funding while Project HOPE distributes the drug and provides other services (7/15)

HepaLife
Technologies Inc.
(Canada; OTC BB:HPLF)

USDA's Agricultural Research Service

Cooperative Research and Development Agreement

To optimize hepatic functionality of the PICM 19 cell line for use on an artificial liver device

Work under the deal's three-year expansion also will involve testing liver cell-specific toxicoloy and metabolism based on the cell line (6/1)

Hybrigenics
SA*
(France)

Shanghai Institute of Materia Medica (China)

Collaboration

To use traditional Chinese medicines to develop therapeutics

Hybrigenics will supply targets and a screening assay and SIMM will provide plant extracts in a cost-sharing arrangement (5/17)**

ImmuneRegen
BioSciences
(subsidiary
of IR BioSciences Holdings
Inc.; OTC BB:IRBO)

University of Arizona College of Medicine

Grant

To test the efficacy of direct muscle injection of Homspera for gamma radiation

ImmuneRegen is funding testing at the university (6/16)

Immunicon
Corp.
(IMMC)

Twente University (the Netherlands)

Development and license agreement

Amended deal to develop an instrument to monitor HIV

The test would be an additional application to Immunicon's Cell-Tracks EasyCount system, which the parties developed (6/17)

Interleukin Genetics
Inc.
(OTC BB:ILGN)

Tufts University

License agreement

Products based on variations in the perilipin gene, which affects body weight

IGI gests exclusive rights to develop and sell tests based on the gene, and may develop nutritional products; terms were not disclosed (6/28)

Interleukin Genetics
Inc.
(OTC BB:ILGN)

Vanderbilt University Medical Center

Collaboration

To evaluate the effectiveness of certain anti-inflammatory agents on endometriosis

IGI has expertise in the genetics of inflammation and Vanderbilt has knowledge of endometriosis disease mechanisms (6/14)

IQ Corp.*
(the Netherlands)

Centers for Disease Control and Prevention

Agreement

The CDC will test four of IQ's anthrax products

The CDC and Department of Health and Human Services will evaluate toxin- neutralizing capacities of the antibodies (6/23)

IQ Corp.*
(the Netherlands)

U.S. Naval Medical Research Center

Cooperative Research and Development Agreement

To develop fully human monoclonal antibodies against biological threat agents

The focus is on development of IQ's Anthraxumab product against anthrax toxin, and on other biological threats (6/2)

Juvaris
BioTherapeutics
Inc.*

Colorado State University

License agreement

To develop therapeutic vaccines using receptor ligands complexed to lipids

CSU gets licensing fees and would get royalties on resulting sales; the mechanism is to activate an array of Toll- like receptors (5/25)

KaloBios
Pharmaceuticals
Inc.*

Ludwig Institute for Cancer Research (Australia branch)

License agreement

Antibody drug candidate for the treatment of autoimmune diseases

The initial focus is rheumatoid arthritis, and human trials are planned for 2H:05; terms of the deal were not disclosed (7/22)

KaloBios
Pharmaceuticals
Inc.*

Medical College of Wisconsin and the University of California at San Francisco

License agreement

Preclinical therapeutic antibody and related intellectual property directed at Pseudomonas aeruginosa

Terms were not disclosed; the antibody is deisgned to neutralize the action of the PcrV protein of the Type III secretion system (6/2)

Kalypsys Inc.*

National Institutes of Health

Access agreement

Kalypsys' platform of lead-discovery solutions

The deal is worth up to $30M to Kalypsys; its technologies will be used by the newly created NIH Chemical Genomics Center (6/9)

KuDOS
Pharmaceuticals
Ltd.*
(UK)

University of Cambridge and Cancer Research Technology Ltd. (both in the UK)

Agreements

Research on DNA repair developed at the university

The deals enable KuDOS' continued access to the research, on which it is developing small moleclues for cancer applications; terms were not disclosed (6/28)

Large Scale
Biology Corp.
(LSBC)

University of Louisville

Collaboration

To develop therapeutics to prevent and treat diseases caused by human papillomaviruses

They will jointly fund the program that will draw on each party's areas of expertise in the field (6/28)

LigoCyte
Pharmaceuticals
Inc.*

Baylor College of Medicine

License agreement

LigoCyte exercised an option to technologies related to norovirus vaccines and drugs

Terms were not disclosed; Baylor has an oral Norwalk virus vaccine candiate in Phase I trials (5/25)

Lynx
Therapeutics
Inc.
(LYNX)

National Institute of Mental Health

Service agreement

To use Lynx's MPSS genomic- analysis technology to study gene expression in the brain

Terms were not disclosed; they will focus on the dorsolateral prefrontal cortex region of the brain that has been implicated in schizophrenia (5/21)

MediGene
AG
(Germany;
FSE:MDG)

University of Chicago

License agreement

Targeting technology that uses herpes simplex virus; for cancer applications

MediGene licensed a specific method of targeting HSV to tumor cells, which it already is using in clinical trials; terms were not disclosed (6/28)

Meridian
Bioscience
Inc.
(VIVO)

Cincinnati Children's Research Foundation

License agreement

Meridian got rights to technology related to the diagnosis of noroviruses

Terms were not disclosed; noro-viruses cause acute gastroenteritis (5/26)

MicroIslet Inc. (AMEX:MII)

University of California at Davis

Collaboration

Deal on islet-cell transplantation therapies for insulin-dependent diabetes

Tests on nonhuman primates will use MicroIslet's technology in pig islets; it will fund work at the university and have a right to license any discoveries (6/23)

Millennium
Pharmaceuticals
Inc.
(MLNM)

Harvard University

Research agreement

Deal on a family of proteasome inhibitors and a related chemical- synthesis process

Millennium gained certain rights to use the process in exchange for milestone fees and royalties on any resulting sales (6/2)

Miraculins
Inc.
(Canada;
VSE:MOM)

Edmonton Prostate and Urological Research Centre (Canada)

Collaboration

Miraculins will get clinical samples from prostate cancer patients matched with samples from control patients

Miraculins will apply its BEST platform to the discovery of prostate cancer markers; terms were not disclosed (7/28)

Nastech
Pharmaceutical Co.
Inc.
(NSTK)

Cedars-Sinai Medical Center

License agreement

Nastech got exclusive rights to peptide YY, a hormone associated with modulation of appetite circuits

CSMC will receive license fees, milestone payments and royalties on any resulting sales; the technology is used in Nastech's investigational PYY3-36 nasal spray for obesity (5/24)

Nucleonics Inc.*

University of California

License agreement

A class of promoters for transcribing expressed interfering RNAs

Nucleonics got exclusive worldwide and sublicense rights to the technology on eukaryotic RNA Pol III promoters in the field; terms were not disclosed (6/3)

PamGene
International BV*
(the Netherlands)

University of Nottingham (UK)

License agreement

PamGene's 3-D flow-through microarray platform

The university licensed the technology to develop multiplex amplifiable probe hybridization on the PamGene platform (7/12)

Peregrine Pharmaceuticals
Inc.
(PPHM)

University of Texas M.D. Anderson Cancer Center

License agreement

Worldwide license covering antiphosphatidylserine antibodies

M.D. Anderson will get an up-front fee and potential milestone and royalty payments; the technology relates to inducing auto-immunity in treating cancer (7/6)

Phytomedical Technologies
Corp.
(subsidiary of Enterprise Technologies Inc.; Canada; TC BB:ETPT)

New York University

Exclusive worldwide rights agreement

For pharmacologically active elements of a muira puama plant extract and ion channel modulators from natural sources

Phytomedical will pay the school a royalty on net sales of all licensed products, and granted it an option to acquire Phytomedical stock; the first compound, BDC 03, has shown its ability in animal studies to reduce body-fat percentage, increase lean muscle mass and lower cholesterol (8/5)

Piramed
Ltd.*
(UK)

The Institute of Cancer Research at Royal Cancer Hospital (UK)

Research collaboration

To develop cancer drugs targeting the P13 kinase-transduction enzyme

They will conduct preclinical pharmacokinetic and efficacy studies of two series of Piramed compounds (5/20)

Plantacor Inc.*

University of Texas M.D. Anderson Cancer Center

License agreement

Plantacor exclusively licensed rights to three preclinical cancer compounds

M.D. Anderson gained an equity position in Plantacor in exchange for rights to liposomal formulations of Curcumin and Emodin and to Calagualine (7/27)

PolyNovo
Biomaterials
Pty. Ltd.*
(subsidiary of Xceed Biotechnology Ltd; Australia; ASX:XBL)

Imperial College London

Collaboration

Deal to further develop PolyNovo's polymer technology for bone repair

The polymers can be formulated as an injectable gel that cures in situ or on demand, and are designed to promote tissue growth and the rate of degradation (7/19)

Power3 Medical Products Inc. (OTC BB: PWRM)

Baylor College of Medicine

License agreement

For serum proteomics methods and biomarkers for diagnosing neuro-degenerative diseases

Power3 paid a licensing fee and would make milestone payments as products develop, as well as royalties on resulting sales (7/20)

QLT Inc. (Canada; QLTI)

National Eye Institute

Cooperative Research and Development Agreement

To study preservative-free triamcinolone acetonide as an adjunct to Visudyne in wet age-related macular degeneration

QLT will fund a 300-patient trial of the combination and gains the option to an exclusive license for certain rights to PFTA in combination with Visudyne (6/2)

Scancell Ltd.* (UK)

Cancer Research Technology Ltd. (UK)

License agreement

Scancell got rights to vaccines against the protein targets Tie-2 and CD55

The targets are implicated in solid tumors; the license is exclusive and worldwide (5/25)

Sequenom Inc. (SQNM)

National Human Genome Research Institute

Cooperative Research and Development Agreement

Sequenom will perform allele-specific gene expression of genes conferring susceptibility to Type II diabetes

The three-year deal builds on previous work between the parties, and will employ Sequenom's MassARRAY technology; terms were not disclosed (7/22)

Targeted Genetics Corp. (TGEN)

National Institutes of Health

License agreement

Patents that cover inverted terminal repeat sequences as a promoter when using adeno-associated viral vectors

Targeted Genetics got an exclusive worldwide license to the technology for any indication; terms were not disclosed (6/4)

Targeted Molecular Diagnostics LLC*

University of Texas M.D. Anderson Cancer Center

Collaboration

To study the utility of cyclin E in predicting outcomes in liver surgery due to metastases from colon cancer

They already have worked in the area of cell-cycle regulators in breast cancer; TMD intends to develop biologic markers (6/21)

TopoTarget A/S* (Denmark)

National Cancer Institute

Cooperative Research and Development Agreement

To develop a series of inhibitors of histone deacetylase

Research will focus on identifying drugs to use with TopoTargets' HDAC inhibitor PXD101, which is in Phase I trials (5/19)**

Trillium Therapeutics Inc.* (Canada)

St. Justine Hospital and the University of Montreal (both in Canada)

License agreement

A series of pro-inflammatory cytokine receptor antagonists

Terms of the deal were not disclosed; Trillium will fund work on the program at the institutions (6/2)

Tripos Inc. (TRPS)

European Molecular Biology Laboratory and the German Cancer Research Centre (both in Germany)

Services agreement

Tripos will apply its chemistry technologies to identify molecular leads at screening facilities in Germany

The German centers brought in the expertise of Tripos in chemistry and small molecules to complement their strength in biology (7/20)

Vertex Pharmaceuticals Inc. (VRTX)

Cystic Fibrosis Foundation

Collaboration expansion

For continued development of Vertex's efforts in CF drug discovery

Vertex will receive $21M through 2005 under an expanded collaboration; Vertex retains all rights to its products (5/24)


Notes:

This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

** Item occurred before the time frame of this chart but was not included in the previous chart.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; VSE = Vancouver Stock Exchange.

No Comments